This site is intended for US healthcare professionals.
Decision Resources. RCC landscape and forecast. December 12, 2019.
Wells JC, Stukalin I, Norton C, et al. Third-line targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2017;71(2):204-220.
D’Aniello C, Berretta M, Cavaliere C, et al. Biomarkers of prognosis and efficacy of anti-angiogenic therapy in metastatic clear cell renal cancer. Front Oncol. 2019;9:1400.
Seruga B, Gan HK, Knox JJ. Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer. Curr Oncol. 2009;16(suppl 1):S52-S59.
Bellesoeur A, Carton E, Alexandre J, Goldwasser F, Huillard O. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Devel Ther. 2017;11:2801-2811.
Massey PR, Okman JS, Wilkerson J, Cowen EW. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Support Care Cancer. 2015;23(6):1827-1835.
Porta C, Levy A, Hawkins R, et al. Impact of adverse events, treatment modiﬁcations, and dose intensity on survival among patients with advanced renal cell carcinoma treated with ﬁrst-line sunitinib: a medical chart review across ten centers in ﬁve European countries. Cancer Med. 2014;3(6):1517-1526.
Tannir NM, Pal SK, Atkins MB. Second-line treatment landscape for renal cell carcinoma: a comprehensive review. Oncologist. 2018;23(5):540-555.
Flynn M, Pickering L, Larkin J, Turajlic S. Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Ther Adv Med Oncol. 2018;10:1758835918777427.
Wong MK, Mohamed AF, Hauber AB, et al. Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. J Med Econ. 2012;15(6):1139-1148.
Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet. 2011;378(9807):1931-1939.
Angulo JC, Shapiro O. The changing therapeutic landscape of metastatic renal cancer. Cancers (Basel). 2019;11(9):1227.
Song X, Tian Y, Li H, Liu B, Zhang A, Hong Y. Research progress on advanced renal cell carcinoma. J Intl Med Res. 2020;48(5):1-10.
Barata PC, De Liano AG, Mendiratta P, et al. The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. Br J Cancer. 2018;119(2):160-163.
Santoni M, Massari F, Di Nunno V, et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:212528.
Pal SK, Vogelzang NJ. Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma. Clin Adv Hematol Oncol. 2013;11(3):146-155.
Chen SC, Kuo PL. Bone metastasis from renal cell carcinoma. Intl J Molecular Sci. 2016;17(6):987.
Xu Y, Zhang Y, Wang X, Kang J, Liu X. Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):168.
Zahoor H, Duddalwar V, D’Souza A, Merseburger AS, Quinn DI. What comes after immuno-oncology therapy for kidney cancer? Kidney Cancer. 2019;3(2):93-102.
Goebell PJ, Staehler M, Müller L, et al. Changes in treatment reality and survival of patients with advanced clear cell renal cell carcinoma − analyses from the German Clinical RCC-Registry. Clin Genitourin Cancer. 2018;16(6):e1101-e1115.
Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1)327-337.
Dienstmann R, Braña I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist. 2011;16(12):1729-1740.
Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs. 2011;11(2):113-126.
Bukowski RM. Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma. Front Oncol. 2012;2:13.
Donskov F, Michaelson MD, Puzanov I, et al. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br J Cancer. 2015;113(11):1571-1580.